Novel anticytomegalovirus activity of immunosuppressant mizoribine and its synergism with ganciclovir

Journal of Pharmacology and Experimental Therapeutics

Volumn 333, Issue 3, 2010, Pages 816-821

  Kuramoto, Takashi ^a   Daikoku, Tohru ^a   Yoshida, Yoshihiro ^a   Takemoto, Masaya ^a   Oshima, Kumi ^b   Eizuru, Yoshito ^c   Kanda, Yoshinobu ^b   Miyawaki, Toshio ^a   Shiraki, Kimiyasu ^a  

^a UNIVERSITY OF TOYAMA   (Japan)

^b JICHI MEDICAL UNIVERSITY   (Japan)

^c KAGOSHIMA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BENZIMIDAVIR; DEOXYGUANOSINE; FOSCARNET; GANCICLOVIR; GUANOSINE; INOSINATE DEHYDROGENASE; MIZORIBINE;

ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOMEGALOVIRUS; DRUG ANTAGONISM; DRUG POTENTIATION; DRUG SENSITIVITY; GENE MUTATION; HUMAN; HUMAN CELL; IN VITRO STUDY; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN DEPLETION; VIRUS CULTURE; VIRUS INHIBITION; VIRUS ISOLATION; VIRUS MUTANT; VIRUS PLAQUE; VIRUS REPLICATION; VIRUS RESISTANCE;

ANTIVIRAL AGENTS; CELL LINE; CYTOMEGALOVIRUS; DNA, VIRAL; DRUG RESISTANCE, VIRAL; DRUG SYNERGISM; GANCICLOVIR; GUANINE; GUANOSINE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MUTATION; PLAQUE ASSAY; RIBONUCLEOSIDES;

EID: 77952330764     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.109.160630     Document Type: Article

References (38)

1. Akiyama T, Okazaki H, Takahashi K, Hasegawa A, Tanabe K, Uchida K, Takahara S, and Toma H (2005) Mizoribine in combination therapy with tacrolimus for living donor renal transplantation: analysis of a nationwide study in Japan. Transplant Proc 37:843-845. (Pubitemid 40590720)
2. Allison AC (2000) Immunosuppressive drugs: the first 50 years and a glance forward. Immunopharmacology 47:63-83.
3. Catapano CV, Dayton JS, Mitchell BS, and Fernandes DJ (1995) GTP depletion induced by IMP dehydrogenase inhibitors blocks RNA-primed DNA synthesis. Mol Pharmacol 47:948-955.
4. Cockley KD, Shiraki K, and Rapp F (1988) A human cytomegalovirus function inhibits replication of herpes simplex virus. J Virol 62:188-195. (Pubitemid 18050808)
5. Dayton JS, Turka LA, Thompson CB, and Mitchell BS (1992) Comparison of the effects of mizoribine with those of azathioprine, 6-mercaptopurine, and mycophenolic acid on T lymphocyte proliferation and purine ribonucleotide metabolism. Mol Pharmacol 41:671-676.
6. Epinette WW, Parker CM, Jones EL, and Greist MC (1987) Mycophenolic acid for psoriasis. A review of pharmacology, long-term efficacy, and safety. J Am Acad Dermatol 17:962-971. (Pubitemid 18021884)
7. European Mycophenolate Mofetil Cooperative Study Group (1995) Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and cortico-steroids for prevention of acute rejection. European Mycophenolate Mofetil Cooperative Study Group. Lancet 345:1321-1325.
8. Gonwa TA (1996) Mycophenolate mofetil for maintenance therapy in kidney transplantation. Clin Transplant 10:128-130. (Pubitemid 26076443)
9. Hantz S, Couvreux A, Champier G, Trapes L, Cotin S, Denis F, Bouaziz S, and Alain S (2009) Conserved domains and structure prediction of human cytomegalovirus UL27 protein. Antivir Ther 14:663-672.
10. Koyama H and Tsuji M (1983) Genetic and biochemical studies on the activation and cytotoxic mechanism of bredinin, a potent inhibitor of purine biosynthesis in mammalian cells. Biochem Pharmacol 32:3547-3553. (Pubitemid 14205362)
11. Kurokawa M, Hozumi T, Tsurita M, Kadota S, Namba T, and Shiraki K (2001) Biological characterization of eugeniin as an anti-herpes simplex virus type 1 compound in vitro and in vivo. J Pharmacol Exp Ther 297:372-379. (Pubitemid 32242598)
12. Mayer K, Reinhard T, Reis A, Voiculescu A, and Sundmacher R (2003) Synergistic antiherpetic effect of acyclovir and mycophenolate mofetil following keratoplasty in patients with herpetic eye disease: first results of a randomised pilot study. Graefes Arch Clin Exp Ophthalmol 241:1051-1054. (Pubitemid 38028902)
13. Mele TS and Halloran PF (2000) The use of mycophenolate mofetil in transplant recipients. Immunopharmacology 47:215-245. (Pubitemid 30394540)
14. Meredith M, Li G, and Metz SA (1997) Inhibition of calcium-induced insulin secretion from intact HIT-T15 or INS-1 beta cells by GTP depletion. Biochem Pharmacol 53:1873-1882. (Pubitemid 27356060)
15. Metz S, Holland S, Johnson L, Espling E, Rabaglia M, Segu V, Brockenbrough JS, and Tran PO (2001) Inosine-5′-monophosphate dehydrogenase is required for mitogenic competence of transformed pancreatic beta cells. Endocrinology 142:193-204. (Pubitemid 32183681)
16. Neyts J, Andrei G, and De Clercq E (1998) The novel immunosuppressive agent mycophenolate mofetil markedly potentiates the antiherpesvirus activities of acyclovir, ganciclovir, and penciclovir in vitro and in vivo. Antimicrob Agents Chemother 42:216-222. (Pubitemid 28114421)
17. Neyts J and De Clercq E (1998) Mycophenolate mofetil strongly potentiates the anti-herpesvirus activity of acyclovir. Antiviral Res 40:53-56. (Pubitemid 28535171)
18. Oshima K, Kanda Y, Kako S, Asano-Mori Y, Watanabe T, Motokura T, Chiba S, Shiraki K, and KurokawaM(2008) Case report: persistent cytomegalovirus (CMV) infection after haploidentical hematopoietic stem cell transplantation using in vivo alemtuzumab: emergence of resistant CMV due to mutations in the UL97 and UL54 genes. J Med Virol 80:1769-1775.
19. Pancheva S, Roeva I, Dundarova D, and Remichkova M (1999) Mycophenolic acid as acyclovir partner for combined inhibition of herpes viruses. Pharmazie 54:632-633. (Pubitemid 29393230)
20. Pancheva SN, Roeva IG, and Remichkova MG (1997) Antiherpetic activity of acyclovir is potentiated by mycophenolic acid. Acta Virol 41:357-358. (Pubitemid 28097335)
21. Plotkin SA, Furukawa T, Zygraich N, and Huygelen C (1975) Candidate cytomegalovirus strain for human vaccination. Infect Immun 12:521-527.
22. Prichard MN (2009) Function of human cytomegalovirus UL97 kinase in viral infection and its inhibition by maribavir. Rev Med Virol 19:215-229.
23. Reardon JE and Spector T (1991) Acyclovir: mechanism of antiviral action and potentiation by ribonucleotide reductase inhibitors. Adv Pharmacol 22:1-27.
24. Sasivimolphan P, Lipipun V, Likhitwitayawuid K, Takemoto M, Pramyothin P, Hattori M, and Shiraki K (2009) Inhibitory activity of oxyresveratrol on wild-type and drug-resistant varicella-zoster virus replication in vitro. Antiviral Res 84:95-97.
25. Shiraki K, Ishibashi M, Okuno T, Hayashi K, Yamanishi K, Takahashi M, Ogino S, and Sonoda T (1991a) Effect of FK-506 on replication of human cytomegalovirus in vitro. J Antibiot (Tokyo) 44:550-552.
26. Shiraki K, Ishibashi M, Okuno T, Kokado Y, Takahara S, Yamanishi K, Sonoda T, and Takahashi M (1990) Effects of cyclosporine, azathioprine, mizoribine, and prednisolone on replication of human cytomegalovirus. Transplant Proc 22:1682-1685. (Pubitemid 20284493)
27. Shiraki K, Ishibashi M, Okuno T, Namazue J, Yamanishi K, Sonoda T, and Takahashi M (1991b) Immunosuppressive dose of azathioprine inhibits replication of human cytomegalovirus in vitro. Arch Virol 117:165-171.
28. Shiraki K, Ishibashi M, Okuno T, Yamanishi K, Takahashi M, Tanaka K, Baba K, Yabuuchi H, Kokado Y, and Takahara S (1991c) Antibody response to the immediate early protein of cytomegalovirus in renal transplant recipients. J Med Virol 34:280-283.
29. Sollinger HW (1995) Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group. Transplantation 60:225-232.
30. Spector T, Averett DR, Nelson DJ, Lambe CU, Morrison RW Jr, St Clair MH, and Furman PA (1985) Potentiation of antiherpetic activity of acyclovir by ribonucleotide reductase inhibition. Proc Natl Acad Sci USA 82:4254-4257. (Pubitemid 15053621)
31. Spector T, Harrington JA, Morrison RW, Jr., Lambe CU, Nelson DJ, Averett DR, Biron K, and Furman PA (1989) 2-Acetylpyridine 5-[(dimethylamino) thiocarbonyl]-thiocarbonohydrazone (A1110U), a potent inactivator of ribonucleotide reductases of herpes simplex and varicella-zoster viruses and a potentiator of acyclovir. Proc Natl Acad Sci USA 86:1051-1055. (Pubitemid 19056288)
32. Suzuki M, Okuda T, and Shiraki K (2006) Synergistic antiviral activity of acyclovir and vidarabine against herpes simplex virus types 1 and 2 and varicella-zoster virus. Antiviral Res 72:157-161. (Pubitemid 44332567)
33. Takahashi K, Ochiai T, Uchida K, Yasumura T, Ishibashi M, Suzuki S, Otsubo O, Isono K, Takagi H, and Oka T (1995) Pilot study of mycophenolate mofetil (RS-61443) in the prevention of acute rejection following renal transplantation in Japanese patients. RS-61443 Investigation Committee-Japan. Transplant Proc 27:1421-1424.
34. Tallarida RJ (2001) Drug synergism: its detection and applications. J Pharmacol Exp Ther 298:865-872. (Pubitemid 32761897)
35. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. (1996) A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. Transplantation 61:1029-1037.
36. Tsuzuki K (2002) Role of mizoribine in renal transplantation. Pediatr Int 44:224-231.
37. Turka LA, Dayton J, Sinclair G, Thompson CB, and Mitchell BS (1991) Guanine ribonucleotide depletion inhibits T cell activation. Mechanism of action of the immunosuppressive drug mizoribine. J Clin Invest 87:940-948.
38. Yukawa TA, Kurokawa M, Sato H, Yoshida Y, Kageyama S, Hasegawa T, Namba T, Imakita M, Hozumi T, and Shiraki K (1996) Prophylactic treatment of cytomegalovirus infection with traditional herbs. Antiviral Res 32:63-70. (Pubitemid 26321142)